丹参注射液对慢性阻塞性肺疾病急性加重期细胞间黏附分子-1表达的影响

目的：研究外周血血清可溶性细胞间黏附分子-1（sICAM-1）与慢性阻塞性肺疾病（COPD）发病的关系、丹参注射液对sICAM-1表达及肺功能的影响。方法：采用ELISA酶联免疫吸附法测定40例COPD急性加重期患者（COPD组），分为COPD组1和COPD组2各20例，给予常规抗感染、解痉、平喘及吸氧等西医综合治疗，COPD组2加用丹参注射液20ml及50％葡萄糖500ml静脉滴注，每日1次。另设20例健康者为对照组。治疗前后分别检测血清sICAM-1的表达及其相应的肺功能（FEV1％）。结果：COPD组患者血清sICAM-1水平明显高于对照组，FEV1％显著低于对照组（均P〈0．01）。治疗10d后，cOPD组与治疗前比较，血清sICAM-1明显下降（P〈0．05，0．01）。COPD组2血清sICAM—1水平低于COPD组1，FEV1％高于COPD组1（P〈0．05）。COPD组血清sICAM-1与FEV1％呈显著负相关。结论：血清sICAM-1参与COPD的发病，丹参能明显阻抑外周血血清sICAM-1的表达，这可能是此类中药具有抗炎活性的又一机理。

The Effects of Slavia Miltiorrhiza Injection on the Expression of sICAM-1 of Patients with COPD

Objective： To investigate the relationship between the expression of sICAM-1 and the pathogenesis of COPD and the effects of Slavia miltiorrhiza injection on the expression of sICAM-1 and FEVI% of patients with COPD. Methods： Forty COPD patients at acute exacerbation phase were divided into conventional treatment group, and Slavia miltiorrhiza-treated group, and 20 normal healthy subjects served as control group. By means of enzyme linked immunosorbent assay （ELISA）, the levels of the sICAM-1 expression was detected, and FEV1% was measured. Results： （1） T.he expression level of sICAM-1 in patients with COPD at acute exacerbation was significantly higher, but the FEV1% lower than in control group （both P〈0. 01）; （2） After treatment for 10 days, the sICAMq expression levels were significantly reduced in COPD group as compared with those before treatment （P〈0.05）. The expression of sICAM-1 was significantly decreased, while FEV1% increased in Slavia miltiorrhiza-treated group as compared with conventional treatment group （P〈0.05）. （3） In COPD groups, the expression of sICAM-1 and FEV1% had an negative correlation. Conclusion： sICAM-1 may play a central role in the pathogenesis of COPD. Slavia milt- iorrhiza injection can obviously inhibit the expression of sICAM-1.